Phathom Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Phathom Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.7. The average 1-year stock price forecast is 133.96% higher than the current stock price, while the lowest is $13 (+28.33%) and the highest is $29 (+186.28%).

Price Target: $23.7 (+133.96%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$13	$23.7	$25.5	$29
Change	+28.33%	+133.96%	+151.73%	+186.28%

Analyst Ratings

The average analyst rating for Phathom Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	8	8	7	7	7
Buy	1	1	2	2	2	2
Hold	2	2	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Stringer Needham	Needham	Buy Maintains $28	Buy	Maintains	$28	+176.41%	Jun 1, 2026
Jenna Davidner Barclays	Barclays	Buy Maintains $18	Buy	Maintains	$18	+77.69%	May 15, 2026
Yatin Suneja Guggenheim	Guggenheim	Buy Reiterates $25	Buy	Reiterates	$25	+146.79%	May 1, 2026
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Buy Reiterates $26	Buy	Reiterates	$26	+156.66%	May 1, 2026
Paul Choi Goldman Sachs	Goldman Sachs	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Apr 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

334.09M

from 175.11M

90.79%

from 175.11M

Revenue Next Year

539.95M

from 334.09M

61.62%

from 334.09M

EPS This Year

-0.04

from -2.06

EPS Next Year

1.44

from -0.04

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	682.00K	55.25M	175.11M	334.09M
Revenue Growth	-	-	-	8,001.47%	216.93%	90.79%
Gross Profit	-	-	515.00K	47.28M	152.51M	267.16M
Gross Margin	-	-	75.51%	85.57%	87.09%	79.97%
Operating Income	-135.08M	-172.44M	-167.31M	-277.47M	-159.99M	8.45M
Net Income	-143.88M	-197.72M	-201.59M	-334.33M	-221.25M	-54.17M
EPS	-	-	-	-	-2.06	-0.04
Free Cash Flow	-96.73M	-93.78M	-90.45M	-203.85M	-107.86M	-45.30M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	338.3M
Avg	334.1M
Low	330.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	93.2%
Avg	90.8%
Low	88.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.04
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-